Tumor Response in the CLARINET Study of Lanreotide Depot/Autogel vs Placebo in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2016年 / 14卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：11 / 12
页数：2
相关论文
共 50 条
  • [1] Tumor response in the CLARINET study of lanreotide depot vs. placebo in patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
    Phan, Alexandria T.
    Dasari, Arvind
    Liyanage, Nilani
    Cox, David
    Lowenthal, Susan Pitman
    Wolin, Edward M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [2] RESPONSE RATES IN THE PHASE 3 CLARINET TRIAL OF LANREOTIDE DEPOT VS PLACEBO IN PATIENTS WITH METASTATIC GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS (GEP-NETS).
    Iwasaki, Michiko
    Wolin, Edward
    Dasari, Arvind
    Liyanage, Nilani
    Lowenthal, Susan Pitman
    Phan, Alexandria
    [J]. ONCOLOGY NURSING FORUM, 2016, 43 (02) : 136 - 136
  • [3] The CLARINET Study - Assessing the Effect of Lanreotide Autogel on Tumor Progression-Free Survival in Patients with Non-Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
    Joelle, Blumberg
    Nilani, Liyanage
    Martyn, Caplin
    [J]. PANCREAS, 2012, 41 (02) : 343 - 343
  • [4] Gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
    Kizilgul, Muhammed
    Delibasi, Tuncay
    [J]. TRANSLATIONAL GASTROINTESTINAL CANCER, 2015, 4 (01) : 39 - 56
  • [5] Real-World Study of Lanreotide Autogel in Routine Practice in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in Hong Kong and Taiwan
    Chen, Jen-Shi
    Bai, Li-Yuan
    Cheng, Hsiao-Hsiang
    Chan, Stephen Lam
    Zou, Ji-Yan
    Shi, Xiaofeng
    Houchard, Aude
    Truong-Thanh, Xuan-Mai
    Chen, Ming-Huang
    [J]. ONCOLOGY AND THERAPY, 2024,
  • [6] OPERA: Observational study of perception of information and quality of life (QoL) in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) starting Lanreotide Autogel (LAN)
    Hautefeuille, V
    Walter, T.
    Do Cao, C.
    Coriat, R.
    Dominguez, S.
    Mineur, L.
    Gueguen, D.
    Houchard, A.
    Mouawad, C.
    Anota, A.
    Hammel, P.
    [J]. JOURNAL OF NEUROENDOCRINOLOGY, 2021, 33 : 136 - 136
  • [7] Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) Preface
    de Herder, Wouter W.
    [J]. BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2012, 26 (06) : 689 - 690
  • [8] Lanreotide depot/autogel (LAN) in midgut neuroendocrine tumors (NETs): A subgroup analysis from the CLARINET study
    Dasari, A.
    Phan, Alexandria T.
    Caplin, Martyn E.
    Pavel, Marianne E.
    Cwikla, Jaroslaw B.
    Raderer, Markus
    Sedlackova, Eva
    Cadiot, Guillaume
    Wolin, Edward M.
    Capdevila, Jaume
    Wall, Lucy
    Rindi, Guido
    Langley, Alison
    Gomez-Panzani, Edda
    Ruszniewski, Philippe B.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [9] Lanreotide Autogel/Depot (LAN) Post-Octreotide Long-Acting Release (OCT) for Safe and Tolerable Treatment of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
    不详
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (12) : 12 - 13
  • [10] Lanreotide Autogel/Depot (LAN) Post-Octreotide Long-Acting Release (OCT) for Safe and Tolerable Treatment of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
    Saif, M. Wasif
    Fu, Julie
    Smith, Melissa
    Maloney, Antonia
    Relias, Valerie
    JWeinstein, Barbara
    Suarez, Yvelisse N.
    Goodman, Martin D.
    Daly, Kevin P.
    [J]. PANCREAS, 2017, 46 (03) : 436 - 436
12345